Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: May 31, 2007

Title: Recombinant DNA Constructs and Methods for Controlling Gene Expression
Numbers: 20070118917, 20070118918
Filed: Oct. 10, 2006
Lead Inventor: Shihshieh Huang, Monsanto
The invention, the patent applications’ abstracts state, “provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous,” the abstracts add. “Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.”

Title: VGLUT-Specific dsRNA Compounds
Numbers: 20070117771
Filed: Sept. 11, 2006
Lead Inventor: Clemens Gillen, Gruenenthal
The patent application, its abstract states, claims “VGLUT-specific dsRNAs capable of triggering the phenomenon of RNA interference, host cells containing these dsRNAs, and pharmaceutical compositions containing these dsRNAs, in particular for the treatment of pain and other diseases associated with VGLUT family members.”

Title: siRNA Molecules and Method of Suppressing Gene Expression with the Use of the Same
Numbers: 20070117767
Filed: Aug. 18, 2004 PCT Filed: Aug. 18, 2004
Inventor: Hirohiko Hohjoh, Japan Health Sciences Foundation
The invention, the patent application’s abstract states, “relates to a double-stranded RNA molecule improved to control the gene expression suppressing effect of an siRNA. The double-stranded RNA molecule of the present invention is designed such that, in a double-stranded RNA molecule capable of suppressing the expression of a target gene in a cell by RNAi, one or more nucleotides in order from the 3'- or 5'-end of the sense strand of double-stranded part in said RNA molecule are not complementary to the antisense strand. Further, in the double-stranded RNA molecule of the present invention, the sense strand of the double-stranded part has adequate number of nucleotides which are complementary to the antisense strand for enabling the hybridization of both strands in the cell.”

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.